BREAST CANCER RESEARCH AND TREATMENT
Scope & Guideline
Innovating Research, Transforming Treatment
Introduction
Aims and Scopes
- Clinical Trials and Patient Outcomes:
Research focused on clinical trials that assess the efficacy and safety of new treatments, including chemotherapy, targeted therapies, and immunotherapies, as well as studies that evaluate patient outcomes and quality of life. - Molecular and Genetic Insights:
Investigations into the molecular and genetic underpinnings of breast cancer, including studies on biomarkers, genetic mutations, and their implications for precision medicine and targeted therapies. - Epidemiology and Risk Factors:
Studies examining the epidemiology of breast cancer, including risk factors such as genetics, lifestyle, and environmental influences, as well as trends in incidence and mortality across different populations. - Innovative Diagnostic Techniques:
Research into new diagnostic methods, including imaging technologies and biomarker assays, that improve early detection and monitoring of breast cancer. - Psychosocial Factors and Survivorship:
Exploration of the psychosocial aspects of breast cancer, including the impact of diagnosis and treatment on mental health, coping mechanisms, and survivorship care. - Health Disparities and Access to Care:
Research addressing disparities in breast cancer outcomes related to socioeconomic status, race, and geographical location, as well as barriers to care and treatment adherence.
Trending and Emerging
- Precision Medicine and Genomics:
An increasing number of studies are focusing on precision medicine approaches, utilizing genomic and molecular profiling to tailor treatments to individual patients, thereby improving outcomes. - Immunotherapy and Targeted Therapies:
Research on immunotherapy and targeted therapies is on the rise, with studies exploring novel agents and combination therapies that enhance the immune response against breast cancer. - Quality of Life and Patient-Centered Care:
There is a growing emphasis on patient-reported outcomes, quality of life assessments, and psychosocial support for breast cancer survivors, highlighting the importance of holistic care. - Digital Health and Telemedicine:
The integration of digital health technologies and telemedicine in breast cancer care has gained traction, particularly in the wake of the COVID-19 pandemic, with studies exploring their effectiveness and patient acceptance. - Health Disparities and Equity in Care:
Emerging research is increasingly addressing health disparities in breast cancer outcomes, focusing on access to care, treatment adherence, and the influence of socioeconomic factors on patient experiences. - Microbiome and Its Role in Cancer:
Research exploring the role of the microbiome in breast cancer development and treatment responses is gaining momentum, indicating a new frontier in understanding cancer biology.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decline in studies focusing solely on traditional chemotherapy regimens, as research increasingly shifts towards personalized medicine and targeted therapies that consider genetic and molecular profiles. - Basic Laboratory Research:
Research that primarily emphasizes basic laboratory findings without direct clinical application or relevance is becoming less prominent as the journal prioritizes translational research that bridges basic science and clinical outcomes. - Epidemiological Studies without Intervention:
Epidemiological studies that do not propose interventions or actionable insights are less frequently published, reflecting a trend towards research that not only identifies risk factors but also suggests ways to mitigate those risks. - Single-Cancer Focus Research:
There is a waning interest in research that examines breast cancer in isolation, with a growing emphasis on studies that consider breast cancer in the context of other comorbid conditions, such as obesity, diabetes, and mental health issues.
Similar Journals
JNCI-Journal of the National Cancer Institute
Advancing cancer research for a brighter tomorrow.JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Advancing the Frontiers of Cancer Research.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.
CANCER INVESTIGATION
Exploring the frontiers of cancer research with precision.CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.
INTERNATIONAL JOURNAL OF CANCER
Leading the charge in innovative cancer solutions.INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.
Cancer Research Communications
Innovating cancer treatment through shared insights.Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.
Oncology Research and Treatment
Transforming oncology through collaboration and discovery.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.
Breast Journal
Championing open access to vital breast health research.The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.
CURRENT PROBLEMS IN CANCER
Elevating Research: Confronting Current Challenges in Cancer ScienceCURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.
eCancerMedicalScience
Connecting minds to conquer cancer.eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.
ONCOLOGY
Exploring the forefront of cancer treatment and research.ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.